Collagen: Emerging Importance in Dry Eye Therapy
Advances in corneal science are reshaping how we understand – and potentially treat – dry eye disease
Collagen, the predominant protein in the human body, plays a crucial role in maintaining corneal integrity and epithelial function. Disruption of collagen in conditions like dry eye disease leads to increased epithelial turnover and inflammation, ultimately compromising corneal barrier function. Collagen mimetic peptides (CMPs) offer a novel therapeutic approach, effectively restoring collagen structure and signaling pathways, thereby enhancing epithelial repair and normalizing tear film stability. Recent clinical trials, including the ST-100 phase 2 trial, demonstrate significant efficacy of CMPs in improving ocular surface integrity and patient comfort in dry eye disease.
1. Collagen is essential for corneal structure and epithelial cell function. 2. In dry eye disease, collagen disruption leads to increased inflammation and epithelial instability. 3. Collagen mimetic peptides can restore collagen architecture and enhance repair. 4. The ST-100 trial showed significant improvements in ocular surface health. 5. CMPs may represent a novel first-line treatment option for various dry eye subtypes.